Biotech · Private company · Brisbane, CA, US
Day One Biopharmaceuticals, Inc.
SEC CIK 0001845337
Track this companyFree. Adds Day One Biopharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials106 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Chemotherapeutic AgentPhase 3 · Low-grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- TovorafenibPhase 3 · Low-grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Emi-LePhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TovorafenibPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- DAY301Phase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Tovorafenib Drug: PimasertibPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- XMT-2056Phase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK PathwayPHASE2 · NOT_YET_RECRUITING · started Aug 30, 2026ClinicalTrials.gov NCT07629167 · fetched Nov 12, 2026
- To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid TumorsPHASE1 · RECRUITING · started Nov 18, 2024ClinicalTrials.gov NCT06752681 · fetched Nov 12, 2026
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)PHASE3 · ACTIVE_NOT_RECRUITING · started Feb 27, 2023ClinicalTrials.gov NCT05566795 · fetched Nov 12, 2026
- A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2PHASE1 · TERMINATED · started Jan 24, 2023ClinicalTrials.gov NCT05514717 · fetched Nov 12, 2026
- Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsPHASE2 · RECRUITING · started Sep 12, 2022ClinicalTrials.gov NCT05465174 · fetched Nov 12, 2026
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsPHASE1_PHASE2 · RECRUITING · started Aug 15, 2022ClinicalTrials.gov NCT05377996 · fetched Nov 12, 2026
- Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsPHASE1 · TERMINATED · started May 2, 2022ClinicalTrials.gov NCT07121829 · fetched Nov 12, 2026
- Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsPHASE2 · TERMINATED · started Jul 15, 2021ClinicalTrials.gov NCT04985604 · fetched Nov 12, 2026
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid TumorsPHASE2 · RECRUITING · started Apr 22, 2021ClinicalTrials.gov NCT04775485 · fetched Nov 12, 2026
- DAY101 In Gliomas and Other TumorsPHASE1 · COMPLETED · started Feb 27, 2018ClinicalTrials.gov NCT03429803 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Apr 23, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 17, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Mar 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 24, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2025 · fetched Nov 12, 2026